United States 119th Congress Status: In Committee Bipartisan · 8 R · 6 D cosponsors

S 527 — Prescription Pricing for the People Act of 2025

Last action — Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced February 11, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Prognosis

Advancing 42% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 14 sponsors

    1 primary, 13 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (8 R · 6 D) — cross-party backing.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Summary

Prescription Pricing for the People Act of 2025This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.

Bill Text

What changed in the latest version

10 added · 4 removed

Plain-language change summary

The updated version of Bill S 527 shows that it was reported in the Senate without any amendments. This change indicates that the bill remained unchanged from its original introduction. This matters because it suggests that the bill has passed through the initial review process in the Senate without alterations to its content.

→
Previous
Latest
527 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S.
527 Reported in Senate (RS)] <DOC> Calendar No.
42 119th CONGRESS 1st Session S.
Hirono, and Mr.
Hirono, Mr.
Lankford) introduced the following bill;
Lankford, Mr.
which was read twice and referred to the Committee on the Judiciary _______________________________________________________________________ A BILL To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.
Boozman, and Mrs.
Blackburn) introduced the following bill;
which was read twice and referred to the Committee on the Judiciary April 10, 2025 Reported by Mr.
Grassley, without amendment _______________________________________________________________________ A BILL To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.
<all>
Calendar No.
42 119th CONGRESS 1st Session S.
527 _______________________________________________________________________ A BILL To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.
_______________________________________________________________________ April 10, 2025 Reported without amendment
⬇ Download PDF
View plain text versions (2)

Action History

  1. Introduced in Senate

  2. Read twice and referred to the Committee on the Judiciary.

  3. Committee on the Judiciary. Ordered to be reported without amendment favorably.

  4. Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.

  5. Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.

  6. Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 13 co-sponsors · 533 not signed on

Sponsors (1)

Co-sponsors (13)

Not signed on (533)

533 members have not signed on to this bill.

Show all 533 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 527 do?
Prescription Pricing for the People Act of 2025This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.
Who sponsors S 527?
S 527 is sponsored by Grassley, Chuck (Republican), Cantwell, Maria (Democratic), Marshall, Roger (Republican), Welch, Peter (Democratic), Tuberville, Tommy (Republican), Coons, Christopher A. (Democratic), Tillis, Thomas (Republican), Blumenthal, Richard (Democratic), Capito, Shelley Moore (Republican), Hirono, Mazie K. (Democratic), Lankford, James (Republican), Boozman, John (Republican), Blackburn, Marsha (Republican), and Warnock, Raphael G. (Democratic).
What is the current status of S 527?
This bill is in committee in the Senate. Introduced February 11, 2025. It must pass committee before a floor vote.
Where can I track S 527?
Track S 527 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 527

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 527

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →